A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis

• Drug: placebo
  
  placebo BID for 16 weeks and then re-randomized into active groups
• Drug: CP-690,550
  
  CP-690,550 5mg BID for 52 weeks
• Drug: CP-690,550
  
  CP-690,550 10mg BID for 52 weeks

• Placebo Comparator: Placebo BID
  
  Intervention: Drug: placebo
• Experimental: 5mg BID CP-690,550
  
  Intervention: Drug: CP-690,550
• Experimental: 10mg BID CP-690,550
  
  Intervention: Drug: CP-690,550

Inclusion Criteria:

• Have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to the first screening procedure.
• Have a PASI score of 12 or greater AND a PGA score of 3 ("moderate") or 4 ("severe") at Baseline (Day 1).
• Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment).

Exclusion Criteria:

• Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis, with the exception of nail psoriasis which is allowed.
• Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.
• Subjects who cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA) for the study are excluded.